Arrowhead Pharmaceuticals (ARWR) Accounts Payables (2010 - 2026)

Arrowhead Pharmaceuticals' Accounts Payables history runs 17 years deep, the most recent figure standing at $30.7 million for Q1 2026.

• Quarterly Accounts Payables rose 208.09% year-over-year to $30.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.7 million (up 208.09% YoY) and the FY2025 annual result came in at $17.7 million, up 55.2% from the prior year.
• Accounts Payables was $30.7 million for Q1 2026 at Arrowhead Pharmaceuticals, down from $32.9 million in the prior quarter.
• Across five years, Accounts Payables topped out at $35.9 million in Q3 2023 and bottomed at $796000.0 in Q4 2022.
• A 5-year average of $15.5 million and a median of $10.6 million in 2022 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2022 — Accounts Payables sank 80.43% — and 2023, when it jumped 1150.56%.
• Arrowhead Pharmaceuticals' Accounts Payables stood at $796000.0 in 2022, then surged by 460.3% to $4.5 million in 2023, then surged by 224.15% to $14.5 million in 2024, then surged by 127.83% to $32.9 million in 2025, then decreased by 6.65% to $30.7 million in 2026.
• Business Quant data shows ARWR's Accounts Payables at $30.7 million in Q1 2026, $32.9 million in Q4 2025, and $17.7 million in Q3 2025.